Unravelling the crosstalk: Anti-fibrotic agents and MAPK inhibitors in the treatment of melanoma.

Melanoma, an aggressive and frequently treatment-resistant kind of skin cancer, poses substantial therapeutic hurdles, especially because it is resistant to inhibitors of the MAPK (mitogen-activated protein kinase) pathway. Even though targeted therapies like BRAF and MEK inhibitors are advanced melanoma therapies, tumour cell plasticity and TME interactions can lead to resistance. Recent research demonstrates that CAFs play a role in fibrotic remodelling in the TME, which promotes tumour growth, immunological suppression, and treatment resistance. Stiffening of ECM because of the pro-fibrotic and pro-tumorigenic substances secreted by CAFs. This, in turn, activates survival pathways and fosters treatment resistance. Anti-fibrotic drugs are meant to treat fibrotic conditions, including idiopathic pulmonary fibrosis, but because of their ability to alter ECM structure and prevent fibroblast activation, they have recently attracted interest in oncology. Targeting fibrotic pathways such as TGF-β, FGF, and PDGF signalling, with medications like nintedanib and pirfenidone, may help overcome the resistance mechanisms associated with MAPK inhibitor therapy. Through the disruption of stromal signalling and the reduction of stress caused by fibrosis, these medicines have the potential to improve drug penetration, decrease tumour plasticity, and restore sensitivity to treatments that target MAPK. This review unravels the complex interactions between MAPK inhibitors and anti-fibrotic drugs in the treatment of melanoma, highlighting how they might work together to remodel the TME and overcome treatment resistance. Implementing this combinatorial method could lead to novel approaches for long-term melanoma control and provide a model for anti-fibrotic-based treatments for other solid cancers.